ERBB2 and breast cancer: PIs on the other hand affect HER2+ breast cancer cells through multiple mechanisms and counteract HER2 activation through different mechanisms compared to TKIs for example through stabilizing the PEST-type protein tyrosine phosphatase BDP1 as we show here (Figure 4C, Figure 5).